Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)
3.21 x 17 3.65 x 2
Post-market by (Cboe BZX)
3.47 -0.10 (-2.80%) 04/16/25 [NASDAQ]
3.21 x 17 3.65 x 2
Post-market 3.75 +0.28 (+8.07%) 17:45 ET
Quote Overview for Wed, Apr 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.37
Day High
3.57
Open 3.55
Previous Close 3.57 3.57
Volume 59,200 59,200
Avg Vol 145,010 145,010
Stochastic %K 54.53% 54.53%
Weighted Alpha -57.69 -57.69
5-Day Change -0.07 (-1.98%) -0.07 (-1.98%)
52-Week Range 2.94 - 10.25 2.94 - 10.25
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 198,535
  • Shares Outstanding, K 55,612
  • Annual Sales, $ 22,600 K
  • Annual Income, $ -86,620 K
  • EBIT $ -103 M
  • EBITDA $ -104 M
  • 60-Month Beta 3.16
  • Price/Sales 8.83
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 361.63% ( -206.63%)
  • Historical Volatility 89.90%
  • IV Percentile 94%
  • IV Rank 59.79%
  • IV High 576.46% on 04/04/25
  • IV Low 42.17% on 09/11/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 20
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 1.31
  • Today's Open Interest 284
  • Open Int (30-Day) 407

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.30
  • Number of Estimates 4
  • High Estimate -0.24
  • Low Estimate -0.34
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +49.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.94 +17.83%
on 04/03/25
Period Open: 4.43
4.71 -26.33%
on 03/17/25
-0.96 (-21.67%)
since 03/14/25
3-Month
2.94 +17.83%
on 04/03/25
Period Open: 4.20
6.66 -47.90%
on 02/18/25
-0.73 (-17.38%)
since 01/16/25
52-Week
2.94 +17.83%
on 04/03/25
Period Open: 6.03
10.25 -66.15%
on 09/20/24
-2.56 (-42.45%)
since 04/16/24

Most Recent Stories

More News
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

FHTX : 3.47 (-2.80%)
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

FHTX : 3.47 (-2.80%)
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

FHTX : 3.47 (-2.80%)
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

FHTX : 3.47 (-2.80%)
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

FHTX : 3.47 (-2.80%)
Foghorn Therapeutics Discontinues Development of FHD-286 for AML, Shifts Focus to Proprietary Pipeline and Collaborations

Foghorn Therapeutics halts FHD-286 development for AML, focusing on proprietary pipeline and Lilly collaboration; strong cash position until 2027.Quiver AI SummaryFoghorn Therapeutics announced the discontinuation...

FHTX : 3.47 (-2.80%)
Foghorn Therapeutics Stock Slides On Cancer Drug Development Halt, But Retail Remains Upbeat

The company stated that while clinical responses were observed, it decided to shift resources to its proprietary pipeline and collaborations with Eli Lilly.

FHTX : 3.47 (-2.80%)
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

FHTX : 3.47 (-2.80%)
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

FHTX : 3.47 (-2.80%)
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

FHTX : 3.47 (-2.80%)

Business Summary

Foghorn Therapeutics Inc. engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 3.77
2nd Resistance Point 3.67
1st Resistance Point 3.57
Last Price 3.47
1st Support Level 3.37
2nd Support Level 3.27
3rd Support Level 3.17

See More

52-Week High 10.25
Fibonacci 61.8% 7.46
Fibonacci 50% 6.60
Fibonacci 38.2% 5.74
Last Price 3.47
52-Week Low 2.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro